About BeiGene (NASDAQ:BGNE)
BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-A333, an humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; and MGCD-0516, a multi-kinase inhibitor. Its preclinical programs consists of targeted therapies and immuno-oncology agents, including an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company has a strategic collaboration with Celgene Corporation to research and develop BeiGene, Ltd.'s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317; and with Merck KGaA to research and develop on BGB-290 and BGB-283. BeiGene, Ltd. was founded in 2010 and is based in George Town, the Cayman Islands.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BGNE
CUSIPN/A
Phone34-59-494-12
Debt
Debt-to-Equity Ratio0.23%
Current Ratio6.09%
Quick Ratio6.02%
Price-To-Earnings
Trailing P/E Ratio-75.33
Forward P/E Ratio-21.51
P/E GrowthN/A
Sales & Book Value
Annual Sales$238.39 million
Price / Sales37.74
Cash FlowN/A
Price / CashN/A
Book Value$15.02 per share
Price / Book11.18
Profitability
EPS (Most Recent Fiscal Year)($2.23)
Net Income$-93,100,000.00
Net MarginsN/A
Return on Equity-18.37%
Return on Assets-12.64%
Miscellaneous
Employees900
Outstanding Shares53,560,000
BeiGene (NASDAQ:BGNE) Frequently Asked Questions
What is BeiGene's stock symbol?
BeiGene trades on the NASDAQ under the ticker symbol "BGNE."
How were BeiGene's earnings last quarter?
BeiGene (NASDAQ:BGNE) released its quarterly earnings results on Wednesday, February, 28th. The company reported ($2.19) EPS for the quarter, missing the consensus estimate of ($1.79) by $0.40. The firm had revenue of $18.17 million for the quarter, compared to analyst estimates of $23 million. View BeiGene's Earnings History.
When is BeiGene's next earnings date?
What price target have analysts set for BGNE?
8 Wall Street analysts have issued 1-year price objectives for BeiGene's shares. Their forecasts range from $86.00 to $200.00. On average, they anticipate BeiGene's stock price to reach $166.00 in the next year. View Analyst Ratings for BeiGene.
What are Wall Street analysts saying about BeiGene stock?
Here are some recent quotes from research analysts about BeiGene stock:
- 1. Maxim Group analysts commented, "BeiGene announced the commercial availability of Celgene’s VIDAZA. Recall that VIDAZA is an injectable nucleoside metabolic inhibitor for patients with Intermediate-2/high-risk myelodysplastic syndrome (MDS), AML with 20-30% bone marrow blasts and chronic myelomonocyte leukemia (CMML). The asset is the third product in BeiGene’s China commercial portfolio along with Abraxane and Revlimid and positions BeiGene to be a leader in the oncology space in China." (2/7/2018)
- 2. According to Zacks Investment Research, "BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. " (1/30/2018)
- 3. Cowen Inc analysts commented, "SGMO reported 3Q17 results and is on track to report first data from the Ph1/2 trials." (11/14/2017)
Who are some of BeiGene's key competitors?
Some companies that are related to BeiGene include UCB (UCBJF), Nektar Therapeutics (NKTR), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), Genmab As (GNMSF), Perrigo (PRGO), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Alkermes (ALKS), Valeant Pharmaceuticals International (VRX), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), Gal�pagos (GLPG) and United Therapeutics (UTHR).
Who are BeiGene's key executives?
BeiGene's management team includes the folowing people:
- Mr. John V. Oyler, Founder, Chairman and Chief Exec. Officer (Age 50)
- Dr. Xiaodong Wang, Co-Founder, Chairman of the Scientific Advisory Board and Director (Age 55)
- Dr. Heng Liang Ph.D., Chief Financial Officer and Chief Strategy Officer (Age 55)
- Mr. Ji Li Ph.D., Exec. VP & Global Head of Bus. Devel. (Age 50)
- Ms. Maggie Liu, Head of Operations and VP
When did BeiGene IPO?
(BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.
Has BeiGene been receiving favorable news coverage?
Press coverage about BGNE stock has been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BeiGene earned a media sentiment score of 0.19 on Accern's scale. They also assigned news articles about the company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of BeiGene?
Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BeiGene's stock price today?
One share of BGNE stock can currently be purchased for approximately $167.99.
How big of a company is BeiGene?
BeiGene has a market capitalization of $9.06 billion and generates $238.39 million in revenue each year. The company earns $-93,100,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. BeiGene employs 900 workers across the globe.
How can I contact BeiGene?
BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 34-59-494-12 or via email at [email protected]
MarketBeat Community Rating for BeiGene (BGNE)
MarketBeat's community ratings are surveys of what our community members think about BeiGene and other stocks. Vote "Outperform" if you believe BGNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BGNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
BeiGene (NASDAQ:BGNE) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for BeiGene in the last 12 months. Their average twelve-month price target is $166.00, suggesting that the stock has a possible downside of 1.18%. The high price target for BGNE is $200.00 and the low price target for BGNE is $86.00. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.88 | 2.86 | 2.86 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $166.00 | $151.20 | $93.00 | $88.00 |
| Price Target Upside: | 1.18% downside | 12.18% downside | 5.60% downside | 19.29% downside |
BeiGene (NASDAQ:BGNE) Consensus Price Target History
BeiGene (NASDAQ:BGNE) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
BeiGene (NASDAQ:BGNE) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
BeiGene (NASDAQ BGNE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 19.90%
Institutional Ownership Percentage: 51.47%
BeiGene (NASDAQ BGNE) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/19/2018 | Howard Liang | CFO | Sell | 40,000 | $160.27 | $6,410,800.00 | 15,872 |  |
| 3/16/2018 | Howard Liang | CFO | Sell | 10,872 | $157.07 | $1,707,665.04 | 15,872 | |
| 3/2/2018 | John Oyler | CEO | Sell | 99,000 | $145.63 | $14,417,370.00 | 93,883 | |
| 2/28/2018 | Ji Li | EVP | Sell | 10,000 | $146.88 | $1,468,800.00 | 10,000 | |
| 2/28/2018 | John Oyler | CEO | Sell | 34,338 | $146.69 | $5,037,041.22 | 93,883 | |
| 1/18/2018 | Bros. Advisors Lp Baker | Director | Buy | 1,980,198 | $101.00 | $199,999,998.00 | | |
| 12/26/2017 | John Oyler | CEO | Sell | 20,137 | $96.46 | $1,942,415.02 | 110,179 | |
| 12/21/2017 | Jane Huang | CMO | Sell | 1,000 | $98.00 | $98,000.00 | 1,000 | |
| 12/13/2017 | Jane Huang | CMO | Sell | 1,500 | $94.25 | $141,375.00 | 1,500 | |
| 12/8/2017 | John Oyler | CEO | Sell | 144,000 | $93.95 | $13,528,800.00 | 255,137 | |
| 12/6/2017 | John Oyler | CEO | Sell | 31,446 | $92.29 | $2,902,151.34 | 255,137 | |
| 12/4/2017 | Jane Huang | CMO | Sell | 1,100 | $86.00 | $94,600.00 | 264,900 | |
| 11/29/2017 | John Oyler | CEO | Sell | 85,906 | $84.66 | $7,272,801.96 | 332,697 | |
| 11/27/2017 | John Oyler | CEO | Sell | 16,581 | $86.76 | $1,438,567.56 | 332,697 | |
| 11/20/2017 | Jane Huang | CMO | Sell | 1,600 | $86.25 | $138,000.00 | 264,900 | |
| 11/16/2017 | Jane Huang | CMO | Sell | 600 | $85.00 | $51,000.00 | 264,900 | |
| 11/15/2017 | John Oyler | CEO | Sell | 150,957 | $80.50 | $12,152,038.50 | 491,891 | |
| 11/13/2017 | Amy C Peterson | CMO | Sell | 3,601 | $82.96 | $298,738.96 | 1,201 | |
| 11/13/2017 | John Oyler | CEO | Sell | 25,054 | $83.06 | $2,080,985.24 | 491,891 | |
| 8/11/2017 | Bros. Advisors Lp Baker | Director | Buy | 176,056 | $71.00 | $12,499,976.00 | | |
| 7/12/2017 | Xiaodong Wang | Director | Sell | 20,000 | $72.44 | $1,448,800.00 | 16,300 | |
| 7/10/2017 | Donald W Glazer | Director | Sell | 10,810 | $72.15 | $779,941.50 | 7,206 | |
| 7/6/2017 | John Oyler | CEO | Sell | 219,400 | $64.82 | $14,221,508.00 | 212,055 | |
| 6/28/2017 | Xiaodong Wang | Director | Sell | 35,000 | $44.95 | $1,573,250.00 | 26,600 | |
| 6/23/2017 | John Oyler | CEO | Sell | 98,500 | $44.16 | $4,349,760.00 | 88,535 | |
| 6/2/2017 | Xiaodong Wang | Director | Sell | 5,539 | $40.00 | $221,560.00 | 55,000 | |
| 5/4/2017 | Xiaodong Wang | Director | Sell | 14,461 | $40.80 | $590,008.80 | 65,030 | |
| 5/1/2017 | John Oyler | CEO | Sell | 36,149 | $40.47 | $1,462,950.03 | 147,440 | |
| 4/5/2017 | Xiaodong Wang | Director | Sell | 11,650 | $36.83 | $429,069.50 | 81,194 | |
| 3/24/2017 | Xiaodong Wang | Director | Sell | 38,107 | $36.96 | $1,408,434.72 | 116,478 | |
| 3/20/2017 | John Oyler | CEO | Sell | 31,989 | $39.39 | $1,260,046.71 | 197,640 | |
| 3/10/2017 | Xiaodong Wang | Director | Sell | 36,892 | $39.89 | $1,471,621.88 | 150,657 | |
| 3/6/2017 | John Oyler | CEO | Sell | 108,999 | $40.91 | $4,459,149.09 | 273,385 | |
| 2/27/2017 | Xiaodong Wang | Director | Sell | 38,351 | $38.19 | $1,464,624.69 | 194,495 | |
| 2/21/2017 | John Oyler | CEO | Sell | 64,963 | $40.55 | $2,634,249.65 | 378,383 | |
| 11/23/2016 | Thomas Malley | Director | Buy | 30,000 | $32.00 | $960,000.00 | 30,000 | |
| 11/18/2016 | Bros. Advisors Lp Baker | Director | Buy | 1,760,495 | $32.00 | $56,335,840.00 | | |
| 9/28/2016 | Donald W Glazer | Director | Sell | 41,463 | $30.66 | $1,271,255.58 | 4,881,997 | |
| 9/27/2016 | Donald W Glazer | Director | Sell | 47,149 | $29.61 | $1,396,081.89 | 4,881,997 | |
| 9/23/2016 | Donald W Glazer | Director | Sell | 36,443 | $31.02 | $1,130,461.86 | 4,881,997 | |
| 9/21/2016 | Donald W Glazer | Director | Sell | 67,252 | $31.42 | $2,113,057.84 | 4,882,000 | |
| 2/8/2016 | Bros. Advisors Lp Baker | Director | Buy | 1,912,680 | $24.00 | $45,904,320.00 | | |
| 2/8/2016 | Howard Liang | CFO | Buy | 65,000 | $1.85 | $120,250.00 | 65,000 | |
| 2/8/2016 | Ruirong Yuan | Insider | Buy | 130,000 | $1.85 | $240,500.00 | 130,000 | |
(Data available from 1/1/2013 forward)
BeiGene (NASDAQ BGNE) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Analysts Expect BeiGene (BGNE) Will Post Earnings of -$1.96 Per Share
www.americanbankingnews.com - April 19 at 5:23 PM |
 | BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory ...
globenewswire.com - April 16 at 4:26 PM |
 | BRIEF-Beigene Presents Clinical Data On Pamiparib In Chinese Patients With Ovarian Cancers At The American ...
www.reuters.com - April 16 at 4:26 PM |
| BeiGene (BGNE) PT Set at $200.00 by Maxim Group
www.americanbankingnews.com - April 16 at 1:19 PM |
| BeiGene Presents Clinical Data on Pamiparib in Chinese Patients with Ovarian Cancers or Triple-Negative Breast ...
globenewswire.com - April 16 at 9:20 AM |
 | BeiGene Presents Clinical Data on Pamiparib in Chinese Patients with Ovarian Cancers or Triple-Negative Breast Cancer at the American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 16 at 9:20 AM |
| BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas
finance.yahoo.com - April 16 at 9:20 AM |
| Piper Jaffray Initiates Coverage on BeiGene (BGNE)
www.americanbankingnews.com - April 13 at 10:13 AM |
 | Benzinga's Top Upgrades, Downgrades For April 13, 2018
www.benzinga.com - April 13 at 9:51 AM |
 | Piper Jaffray Starts BeiGene, Ltd. (BGNE) at Overweight
www.streetinsider.com - April 13 at 9:51 AM |
| These 3 Biotech Stocks Are Up More Than 500% Over the Last 3 Years
finance.yahoo.com - April 13 at 9:51 AM |
| BeiGene (BGNE) Coverage Initiated at Ladenburg Thalmann
www.americanbankingnews.com - April 13 at 12:25 AM |
| BeiGene (BGNE) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 11 at 9:38 AM |
| UPDATE: BeiGene, Ltd. (BGNE) PT Raised to $200 at Maxim Group
www.streetinsider.com - April 10 at 4:28 PM |
| BeiGene (BGNE) Price Target Raised to $200.00
www.americanbankingnews.com - April 10 at 12:30 PM |
 | BeiGene initiates Phase 2 trial of tislelizumab in patients with previously treated hepatocellular carcinoma
seekingalpha.com - April 10 at 8:27 AM |
| What Drove BeiGene Stock in March 2018?
finance.yahoo.com - April 9 at 4:26 PM |
| Analysts Expect Beigene Ltd (BGNE) Will Announce Quarterly Sales of $16.27 Million
www.americanbankingnews.com - April 4 at 2:30 AM |
| BRIEF-BeiGene Appoints J. Samuel Su To Its Board Of Directors
www.reuters.com - April 3 at 9:46 AM |
| BeiGene (BGNE) Names J. Samuel Su to Board
www.streetinsider.com - April 3 at 9:46 AM |
| BeiGene Appoints J. Samuel Su to its Board of Directors
finance.yahoo.com - April 3 at 9:46 AM |
| Zacks: Brokerages Anticipate Beigene Ltd (BGNE) Will Announce Earnings of -$1.94 Per Share
www.americanbankingnews.com - April 2 at 5:16 PM |
| Beigene (BGNE) Downgraded by ValuEngine
www.americanbankingnews.com - March 31 at 1:04 PM |
| Beigene (BGNE) Given a $120.00 Price Target at Maxim Group
www.americanbankingnews.com - March 27 at 12:39 AM |
| Beigene (BGNE) Upgraded to "Buy" by BidaskClub
www.americanbankingnews.com - March 26 at 9:15 AM |
| Beigene (BGNE) Upgraded at ValuEngine
www.americanbankingnews.com - March 25 at 8:44 PM |
| Maxim Group Reiterates Buy Rating for Beigene (BGNE)
www.americanbankingnews.com - March 24 at 2:13 PM |
| Beigene (BGNE) Upgraded by BidaskClub to "Strong-Buy"
www.americanbankingnews.com - March 23 at 11:20 PM |
| Beigene (BGNE) Given Overweight Rating at Morgan Stanley
www.americanbankingnews.com - March 21 at 12:20 PM |
| Beigene Ltd (BGNE) CFO Howard Liang Sells 10,872 Shares
www.americanbankingnews.com - March 20 at 7:32 PM |
| Beigene Ltd (BGNE) CFO Howard Liang Sells 40,000 Shares
www.americanbankingnews.com - March 20 at 7:32 PM |
| Today’s Research Reports on Trending Tickers: BeiGene and Exact Sciences
finance.yahoo.com - March 20 at 9:40 AM |
| Beigene Ltd (BGNE) Expected to Post Quarterly Sales of $16.27 Million
www.americanbankingnews.com - March 18 at 4:22 AM |
| Beigene Ltd (BGNE) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 17 at 9:47 AM |
| Analysts Anticipate Beigene Ltd (BGNE) to Post -$1.94 EPS
www.americanbankingnews.com - March 16 at 3:52 PM |
| Traders Buy Large Volume of Call Options on Beigene (BGNE)
www.americanbankingnews.com - March 16 at 7:18 AM |
| University of Notre Dame DU Lac Cuts Position in Beigene Ltd (BGNE)
www.americanbankingnews.com - March 6 at 10:02 AM |
| Ladenburg Thalmann Financial Services Reiterates Buy Rating for Beigene (BGNE)
www.americanbankingnews.com - March 6 at 12:54 AM |
| Beigene Ltd (BGNE) Holdings Cut by The Manufacturers Life Insurance Company
www.americanbankingnews.com - March 5 at 1:56 PM |
| China's Tasly to list biotech arm in $1 bln Hong Kong IPO - sources
finance.yahoo.com - March 5 at 9:41 AM |
| Beigene Ltd (BGNE) Forecasted to Post Q1 2018 Earnings of ($1.87) Per Share
www.americanbankingnews.com - March 5 at 2:56 AM |
| Emory University Sells 1,105 Shares of Beigene Ltd (BGNE)
www.americanbankingnews.com - March 4 at 2:59 PM |
| Beigene Ltd (BGNE) CEO John Oyler Sold $14.4 million of Shares
finance.yahoo.com - March 3 at 9:24 AM |
| Beigene Ltd (BGNE) CEO John Oyler Sells 99,000 Shares
www.americanbankingnews.com - March 2 at 9:22 PM |
| Insider Selling: Beigene Ltd (BGNE) EVP Sells 10,000 Shares of Stock
www.americanbankingnews.com - March 2 at 9:22 PM |
| Beigene Ltd (BGNE) CEO John Oyler Sells 34,338 Shares
www.americanbankingnews.com - March 2 at 9:22 PM |
| Beigene's (BGNE) "Hold" Rating Reaffirmed at Robert W. Baird
www.americanbankingnews.com - March 1 at 5:40 PM |
| Beigene (BGNE) Announces Quarterly Earnings Results
www.americanbankingnews.com - March 1 at 11:38 AM |
| BeiGene Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 28 at 5:00 PM |
| BeiGene Announces Approval of REVLIMID® for Newly Diagnosed Multiple Myeloma in China
finance.yahoo.com - February 28 at 9:24 AM |
BeiGene (NASDAQ:BGNE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
BeiGene (NASDAQ:BGNE) Income Statement, Balance Sheet and Cash Flow Statement
BeiGene (NASDAQ BGNE) Stock Chart for Friday, April, 20, 2018
Loading chart…
